Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 36, 2019 - Issue 4
Submit an article Journal homepage
312
Views
7
CrossRef citations to date
0
Altmetric
Articles

Effect of imatinib on growth in children with chronic myeloid leukemia

Deepthi BodduDepartment of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Priyakumari ThankamonyDepartment of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, IndiaCorrespondence[email protected]
,
C.S. GuruprasadDepartment of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Manjusha NairDepartment of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Binitha RajeswariDepartment of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
&
Shwetha SeetharamDepartment of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
Pages 189-197 | Received 06 Jun 2018, Accepted 16 Apr 2019, Published online: 12 Jul 2019

References

  • Druker BJ, Gathmann I, Kantarjian H, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417.
  • Jaeger BAS, Tauer JT, Ulmer A, Kuhlisch E, Roth HJ, Suttorp M. Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monit. 2012;18(12):CR721–CR728. doi:10.12659/MSM.883599.
  • Mughal T. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biol Targets Ther. 2010;4:315–323.
  • Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: Use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology. 2010;2010(1):368–376. doi:10.1182/asheducation-2010.1.368.
  • Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2012;59(3):481–484. doi:10.1002/pbc.23389.
  • Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159(4):676–681. doi:10.1016/j.jpeds.2011.03.046.
  • shashi.bhushan. State/UT-wise details of Prevalence of Malnutrition among Children under five years of age as per NFHS-3 and NFHS-4 from 2005-06 to 2015-16 (From: Ministry of Women and Child Development) [Internet]. data.gov.in. https://data.gov.in/resources/state-ut-wise-details-prevalence-malnutrition-among-children-under-five-years-age-nfhs-3. 2018. Cited January 15, 2019.
  • Greulich W, Pyle S. Radiograph Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press; 1959.
  • Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041–6051. doi:10.1200/JCO.2009.25.0779.
  • Narayanan KR, Bansal D, Walia R, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer. 2013;60(7):1148–1153. doi:10.1002/pbc.24397.
  • Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia: TKI-associated endocrinopathies in pediatric CML. Pediatr Blood Cancer. 2016;63(8):1332–1338. Augdoi:10.1002/pbc.26028.
  • Mariani S, Giona F, Basciani S, Brama M, Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet. 2008;372(9633):111–112. doi:10.1016/S0140-6736(08)61023-5.
  • Hobernicht SL, Schweiger B, Zeitler P, Wang M, Hunger SP. Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy. Pediatr Blood Cancer. 2011;56(4):671–673. doi:10.1002/pbc.22945.
  • Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, Boston BA. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer. 2012;59(5):840–845. doi:10.1002/pbc.24121.
  • Millot F, Guilhot J, Baruchel A, et al. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer. 2014;50(18):3206–3211. doi:10.1016/j.ejca.2014.10.007.
  • Tauer JT, Nowasz C, Sedlacek P, et al. Impairment of longitudinal growth by tyrosine kinase inhibitor (TKI) treatment – Data from a large pediatric cohort with Chronic Myeloid Leukemia (CML). Blood. 2014;124(21):522–522.
  • Millot F, Baruchel A, Guilhot J, et al. imatinib is efficient but has a negative impact on growth in children with previously untreated chronic myelogenous leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial. Blood. 2009;114(22):863–863.
  • Kebapcilar L, Bilgir O, Alacacioglu I, et al. Does imatinib mesylate therapy cause growth hormone deficiency? Med Princ Pract. 2009;18(5):360–363. doi:10.1159/000226288.
  • Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354(19):2006–2013.
  • Choeyprasert W, Yansomdet T, Natesirinilkul R, Wejaphikul K, Charoenkwan P. Adverse effects of imatinib in children with chronic myelogenous leukemia. Pediatr Int off J Jpn Pediatr Soc. 2017;59(3):286–292. doi:10.1111/ped.13136.
  • Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height at ages 2-9 years allowing for heights of parents. Arch Dis Child. 1970;45(244):755–762. doi:10.1136/adc.45.244.755.
  • Wright CM, Cheetham TD. The strengths and limitations of parental heights as a predictor of attained height. Arch Dis Child. 1999;81(3):257–260.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.